Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 28

1.

HIV-1 VACCINES. HIV-1 neutralizing antibodies induced by native-like envelope trimers.

Sanders RW, van Gils MJ, Derking R, Sok D, Ketas TJ, Burger JA, Ozorowski G, Cupo A, Simonich C, Goo L, Arendt H, Kim HJ, Lee JH, Pugach P, Williams M, Debnath G, Moldt B, van Breemen MJ, Isik G, Medina-Ramírez M, Back JW, Koff WC, Julien JP, Rakasz EG, Seaman MS, Guttman M, Lee KK, Klasse PJ, LaBranche C, Schief WR, Wilson IA, Overbaugh J, Burton DR, Ward AB, Montefiori DC, Dean H, Moore JP.

Science. 2015 Jul 10;349(6244):aac4223. doi: 10.1126/science.aac4223. Epub 2015 Jun 18.

PMID:
26089353
2.

Selection of unadapted, pathogenic SHIVs encoding newly transmitted HIV-1 envelope proteins.

Del Prete GQ, Ailers B, Moldt B, Keele BF, Estes JD, Rodriguez A, Sampias M, Oswald K, Fast R, Trubey CM, Chertova E, Smedley J, LaBranche CC, Montefiori DC, Burton DR, Shaw GM, Markowitz M, Piatak M Jr, KewalRamani VN, Bieniasz PD, Lifson JD, Hatziioannou T.

Cell Host Microbe. 2014 Sep 10;16(3):412-8. doi: 10.1016/j.chom.2014.08.003.

PMID:
25211081
3.

Passive transfer of modest titers of potent and broadly neutralizing anti-HIV monoclonal antibodies block SHIV infection in macaques.

Shingai M, Donau OK, Plishka RJ, Buckler-White A, Mascola JR, Nabel GJ, Nason MC, Montefiori D, Moldt B, Poignard P, Diskin R, Bjorkman PJ, Eckhaus MA, Klein F, Mouquet H, Cetrulo Lorenzi JC, Gazumyan A, Burton DR, Nussenzweig MC, Martin MA, Nishimura Y.

J Exp Med. 2014 Sep 22;211(10):2061-74. doi: 10.1084/jem.20132494. Epub 2014 Aug 25.

4.

Tetherin antagonism by Vpu protects HIV-infected cells from antibody-dependent cell-mediated cytotoxicity.

Arias JF, Heyer LN, von Bredow B, Weisgrau KL, Moldt B, Burton DR, Rakasz EG, Evans DT.

Proc Natl Acad Sci U S A. 2014 Apr 29;111(17):6425-30. doi: 10.1073/pnas.1321507111. Epub 2014 Apr 14.

5.

HIV-1 Vpu antagonism of tetherin inhibits antibody-dependent cellular cytotoxic responses by natural killer cells.

Alvarez RA, Hamlin RE, Monroe A, Moldt B, Hotta MT, Rodriguez Caprio G, Fierer DS, Simon V, Chen BK.

J Virol. 2014 Jun;88(11):6031-46. doi: 10.1128/JVI.00449-14. Epub 2014 Mar 12.

6.

Prevention of cell death by antibodies selected from intracellular combinatorial libraries.

Xie J, Yea K, Zhang H, Moldt B, He L, Zhu J, Lerner RA.

Chem Biol. 2014 Feb 20;21(2):274-83. doi: 10.1016/j.chembiol.2013.12.006. Epub 2014 Jan 16.

7.

The Neonatal Fc receptor (FcRn) enhances human immunodeficiency virus type 1 (HIV-1) transcytosis across epithelial cells.

Gupta S, Gach JS, Becerra JC, Phan TB, Pudney J, Moldoveanu Z, Joseph SB, Landucci G, Supnet MJ, Ping LH, Corti D, Moldt B, Hel Z, Lanzavecchia A, Ruprecht RM, Burton DR, Mestecky J, Anderson DJ, Forthal DN.

PLoS Pathog. 2013;9(11):e1003776. doi: 10.1371/journal.ppat.1003776. Epub 2013 Nov 21. Erratum in: PLoS Pathog. 2013 Nov;9(11). doi:10.1371/annotation/31430955-703b-484a-96eb-e180f917d683.

8.

DNA transposition by protein transduction of the piggyBac transposase from lentiviral Gag precursors.

Cai Y, Bak RO, Krogh LB, Staunstrup NH, Moldt B, Corydon TJ, Schrøder LD, Mikkelsen JG.

Nucleic Acids Res. 2014 Feb;42(4):e28. doi: 10.1093/nar/gkt1163. Epub 2013 Nov 21.

9.

SnapShot: broadly neutralizing antibodies.

Sok D, Moldt B, Burton DR.

Cell. 2013 Oct 24;155(3):728-728.e1. doi: 10.1016/j.cell.2013.10.009. Epub 2013 Oct 24. No abstract available.

10.

Therapeutic efficacy of potent neutralizing HIV-1-specific monoclonal antibodies in SHIV-infected rhesus monkeys.

Barouch DH, Whitney JB, Moldt B, Klein F, Oliveira TY, Liu J, Stephenson KE, Chang HW, Shekhar K, Gupta S, Nkolola JP, Seaman MS, Smith KM, Borducchi EN, Cabral C, Smith JY, Blackmore S, Sanisetty S, Perry JR, Beck M, Lewis MG, Rinaldi W, Chakraborty AK, Poignard P, Nussenzweig MC, Burton DR.

Nature. 2013 Nov 14;503(7475):224-8. doi: 10.1038/nature12744. Epub 2013 Oct 30.

11.

Simplifying the synthesis of SIgA: combination of dIgA and rhSC using affinity chromatography.

Moldt B, Saye-Francisco K, Schultz N, Burton DR, Hessell AJ.

Methods. 2014 Jan 1;65(1):127-32. doi: 10.1016/j.ymeth.2013.06.022. Epub 2013 Jun 25.

12.

Familial hypercholesterolemia and atherosclerosis in cloned minipigs created by DNA transposition of a human PCSK9 gain-of-function mutant.

Al-Mashhadi RH, Sørensen CB, Kragh PM, Christoffersen C, Mortensen MB, Tolbod LP, Thim T, Du Y, Li J, Liu Y, Moldt B, Schmidt M, Vajta G, Larsen T, Purup S, Bolund L, Nielsen LB, Callesen H, Falk E, Mikkelsen JG, Bentzon JF.

Sci Transl Med. 2013 Jan 2;5(166):166ra1. doi: 10.1126/scitranslmed.3004853.

13.

Highly potent HIV-specific antibody neutralization in vitro translates into effective protection against mucosal SHIV challenge in vivo.

Moldt B, Rakasz EG, Schultz N, Chan-Hui PY, Swiderek K, Weisgrau KL, Piaskowski SM, Bergman Z, Watkins DI, Poignard P, Burton DR.

Proc Natl Acad Sci U S A. 2012 Nov 13;109(46):18921-5. doi: 10.1073/pnas.1214785109. Epub 2012 Oct 25.

14.

Protection against high-dose highly pathogenic mucosal SIV challenge at very low serum neutralizing titers of the antibody-like molecule CD4-IgG2.

Poignard P, Moldt B, Maloveste K, Campos N, Olson WC, Rakasz E, Watkins DI, Burton DR.

PLoS One. 2012;7(7):e42209. doi: 10.1371/journal.pone.0042209. Epub 2012 Jul 27.

15.

A nonfucosylated variant of the anti-HIV-1 monoclonal antibody b12 has enhanced FcγRIIIa-mediated antiviral activity in vitro but does not improve protection against mucosal SHIV challenge in macaques.

Moldt B, Shibata-Koyama M, Rakasz EG, Schultz N, Kanda Y, Dunlop DC, Finstad SL, Jin C, Landucci G, Alpert MD, Dugast AS, Parren PW, Nimmerjahn F, Evans DT, Alter G, Forthal DN, Schmitz JE, Iida S, Poignard P, Watkins DI, Hessell AJ, Burton DR.

J Virol. 2012 Jun;86(11):6189-96. doi: 10.1128/JVI.00491-12. Epub 2012 Mar 28.

16.

A panel of IgG1 b12 variants with selectively diminished or enhanced affinity for Fcγ receptors to define the role of effector functions in protection against HIV.

Moldt B, Schultz N, Dunlop DC, Alpert MD, Harvey JD, Evans DT, Poignard P, Hessell AJ, Burton DR.

J Virol. 2011 Oct;85(20):10572-81. doi: 10.1128/JVI.05541-11. Epub 2011 Aug 17.

17.

Limited or no protection by weakly or nonneutralizing antibodies against vaginal SHIV challenge of macaques compared with a strongly neutralizing antibody.

Burton DR, Hessell AJ, Keele BF, Klasse PJ, Ketas TA, Moldt B, Dunlop DC, Poignard P, Doyle LA, Cavacini L, Veazey RS, Moore JP.

Proc Natl Acad Sci U S A. 2011 Jul 5;108(27):11181-6. doi: 10.1073/pnas.1103012108. Epub 2011 Jun 20.

18.

Comparative genomic integration profiling of Sleeping Beauty transposons mobilized with high efficacy from integrase-defective lentiviral vectors in primary human cells.

Moldt B, Miskey C, Staunstrup NH, Gogol-Döring A, Bak RO, Sharma N, Mátés L, Izsvák Z, Chen W, Ivics Z, Mikkelsen JG.

Mol Ther. 2011 Aug;19(8):1499-510. doi: 10.1038/mt.2011.47. Epub 2011 Apr 5.

19.

Targeting of human interleukin-12B by small hairpin RNAs in xenografted psoriatic skin.

Bak RO, Stenderup K, Rosada C, Petersen LB, Moldt B, Dagnæs-Hansen F, Jakobsen M, Kamp S, Jensen TG, Dam TN, Mikkelsen JG.

BMC Dermatol. 2011 Feb 27;11:5. doi: 10.1186/1471-5945-11-5.

20.

A robust, high-throughput assay to determine the phagocytic activity of clinical antibody samples.

Ackerman ME, Moldt B, Wyatt RT, Dugast AS, McAndrew E, Tsoukas S, Jost S, Berger CT, Sciaranghella G, Liu Q, Irvine DJ, Burton DR, Alter G.

J Immunol Methods. 2011 Mar 7;366(1-2):8-19. doi: 10.1016/j.jim.2010.12.016. Epub 2010 Dec 27. Erratum in: J Immunol Methods. 2012 Feb 28;376(1-2):156.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk